What is IGF-1 LR3?
IGF-1 LR3 is an engineered version of insulin-like growth factor 1 (IGF-1, a growth factor the liver makes in response to growth hormone) designed for cell culture and animal research, with modifications that stop it binding to IGF binding proteins (blood proteins that normally hold IGF-1 in check) so more of it reaches the receptor. In rats it was about 2.5 times more anabolic (tissue building) than native IGF-1, but no human has received it in a published study, so its evidence grade is animal-only. It has never been reviewed by FDA, cannot be compounded (custom-made by a pharmacy), and IGF-1 and its analogs are prohibited by WADA under section S2, the anti-doping class for growth factors. The approved human IGF-1 product, mecasermin, is a different molecule with a narrow pediatric indication (a rare growth disorder in children).
IGF-1 LR3 is a recombinant 83 amino acid analog of human IGF-1 with a 13 amino acid N-terminal extension and arginine substituted for glutamate at position 3, engineered in 1992 to escape IGF binding proteins. It is also known as Long R3 IGF-1, Long [Arg3]-IGF-I, LR3IGF-I, LR3-IGF-1, Long arginine 3 insulin-like growth factor 1.
How does it work?
IGF-1 activates the IGF-1 receptor to stimulate protein synthesis, cell proliferation, and glucose uptake, and inhibits protein breakdown. In blood, most native IGF-1 is bound to IGF binding proteins, which limit its free concentration and half life. LR3 IGF-1 binds those proteins very poorly, so despite binding the IGF-1 receptor about 3 fold less well than IGF-1, it is more potent in vivo because more of it is free to act. It also binds the insulin receptor, which is one basis for its hypoglycemia risk.
| Cluster | Tissue repair and healing |
|---|---|
| Routes | Subcutaneous or intramuscular injection (as sold); Continuous subcutaneous infusion (rat studies); Cell culture reagent (its intended use) |
| Conditions studied | Muscle recovery and injury |
| Record | v3, reviewed, verified Sep 23, 2026 |
What does the evidence say about IGF-1 LR3?
The evidence is 1990s in vitro and rat work from the group that engineered the analog. In rat myoblasts and hepatoma cells LR3 IGF-1 was more potent than IGF-1 at stimulating protein and DNA synthesis, and in dexamethasone treated catabolic rats it was about 2.5 fold more anabolic than IGF-1 on body weight and nitrogen retention, with increased gut weight. No human study of LR3 IGF-1 exists. Human data on IGF-1 itself come from mecasermin, the FDA approved recombinant IGF-1 for severe primary IGF-1 deficiency in children, whose label documents hypoglycemia, tonsillar hypertrophy, intracranial hypertension, and a contraindication in active or suspected cancer.
| Evidence type | Indexed studies | Participants (human) |
|---|---|---|
| Human randomized trials | 0 | n/a |
| Human observational studies | 0 | n/a |
| Animal studies | 2 | n/a |
| All indexed studies | 2 | n/a |
Human evidence
No indexed human study of IGF-1 LR3 identified. The nearest human evidence is the labeling for mecasermin (Increlex), a recombinant native IGF-1 approved in 2005 for children with severe primary IGF-1 deficiency, which lists hypoglycemia as the most common adverse reaction and contraindicates use in active or suspected malignancy; those findings concern a different, approved molecule and a pediatric population.
Animal evidence
In L6 rat myoblasts, Long [Arg3]-IGF-1 and other N-terminal analogs were more potent than IGF-1 at stimulating protein and DNA synthesis and inhibiting protein breakdown, with the greatest advantage in cells that secrete IGF binding proteins. In dexamethasone treated rats, LR3 IGF-1 and des(1-3) IGF-1 were about 2.5 fold more potent than IGF-1 at restoring body weight and nitrogen retention, decreased muscle protein breakdown, and increased gut weight by up to 45%, despite LR3 IGF-1 binding the type 1 IGF receptor 3 fold less well.
Key studies
| Study | Design and population | Outcome | Grade |
|---|---|---|---|
| Novel recombinant fusion protein analogues of insulin-like growth factor (IGF)-I indicate the relative importance of IGF-binding protein and receptor binding for enhanced biological potency1992 PMID 1378742 | In vitro cell culture (rat myoblasts, hepatoma cells, chicken fibroblasts) with receptor and binding protein assaysCultured cell lines | Long [Arg3]-IGF-1 was more potent than IGF-1 at stimulating protein and DNA synthesis in cells that secrete IGF binding proteins, but less potent in cells that do not | Evidence: Animal-only evidence |
| Insulin-like growth factor-I (IGF-I) and especially IGF-I variants are anabolic in dexamethasone-treated rats1992 PMID 1371669 | Rat catabolic model with continuous subcutaneous infusion for 7 daysDexamethasone treated 150 g male rats | LR3 IGF-1 and des(1-3) IGF-1 were about 2.5 fold more potent than IGF-1 on body weight and nitrogen retention; muscle protein breakdown fell and gut weight rose up to 45% | Evidence: Animal-only evidence |
Conditions studied
| Condition | Grade | Note |
|---|---|---|
| Muscle recovery and injury | Evidence: Animal-only evidence | Long acting IGF-1 analog used in cell culture; no human clinical trials; WADA prohibited. |
Is IGF-1 LR3 legal in the United States?
FDA and compounding status
Never submitted to or reviewed by FDA for human use. IGF-1 LR3 is not a component of an approved drug (mecasermin is native IGF-1, a different molecule), has no USP monograph, and has not been placed on the 503A bulks list, so a 503A pharmacy has no federal basis to compound it, and it is not eligible for 503B outsourcing. It is sold as a cell culture reagent and research chemical, which is an unapproved drug when sold for human use.
WADA status
WADA prohibited. Athletes subject to anti-doping testing should treat this as prohibited at all times unless the current prohibited list says otherwise.
Regulatory timeline
- WADA
WADA publishes the 2027 Prohibited List
WADA published the 2027 Prohibited List on September 21, 2026, and it takes effect January 1, 2027. The S2 peptide hormone and growth factor classes are unchanged. BPC-157 is still named under S0, and MOTS-c is still named under S4.4 as an activator of AMP-activated protein kinase. WADA added a note that many peptides without approval for human use fall under S0 or another section, and that a peptide not named on the list may still be prohibited. GLP-1 receptor agonists such as semaglutide and tirzepatide are still not on the list.
- WADA
WADA 2026 Prohibited List takes effect
The 2026 WADA Prohibited List took effect on January 1, 2026 and continues to prohibit the S2 peptide hormone and growth factor classes (GHRH analogs, growth hormone secretagogues, GH fragments, IGF-1 and analogs, MGF, thymosin beta-4 and derivatives, hCG and GnRH-class releasing factors in males), myostatin inhibitors, insulin and the AMPK activator MOTS-c under S4, desmopressin under S5, and BPC-157 under S0. GLP-1 receptor agonists such as semaglutide and tirzepatide are not on the list.
- WADA
WADA 2025 Prohibited List keeps peptide hormones and growth factors banned at all times
The 2025 WADA Prohibited List took effect on January 1, 2025. Section S2 (peptide hormones, growth factors, related substances and mimetics) covers GHRH analogs such as CJC-1295, sermorelin, and tesamorelin, growth hormone secretagogues such as ipamorelin, GHRP-2, GHRP-6, hexarelin, and ibutamoren (MK-677), growth hormone fragments such as AOD-9604, growth factors including IGF-1 and its analogs, MGF, and thymosin beta-4 and its derivatives, including TB-500, and chorionic gonadotropin and releasing factors such as gonadorelin and kisspeptin (prohibited in males). Myostatin inhibitors such as ACE-031 fall under S4, insulin under S4 metabolic modulators, desmopressin under S5, and BPC-157 remains an S0 non-approved substance.
Full tracker for IGF-1 LR3 or the category-wide tracker.
Email me when IGF-1 LR3's status changes
Email only. Alerts have not started yet; we will ask you to confirm before the first one. Unsubscribe any time.
What published studies of IGF-1 LR3 used
Ranges below are reported from published studies and labeling only. PeptideAgent does not recommend doses or protocols.
Not established in human literature. Rat studies used continuous subcutaneous infusion by osmotic pump at microgram per day doses scaled to 150 g animals; these do not translate to a human dose. Mecasermin, the approved native IGF-1, is dosed in children at 0.04 to 0.12 mg/kg twice daily with meals under specialist supervision, and that regimen does not apply to LR3 IGF-1.
Routes reported
| # | Route |
|---|---|
| 1 | Subcutaneous or intramuscular injection (as sold) |
| 2 | Continuous subcutaneous infusion (rat studies) |
| 3 | Cell culture reagent (its intended use) |
IGF-1 LR3 risks and side effects
Side effects
| # | Reported side effect |
|---|---|
| 1 | No human safety data for LR3 IGF-1 |
| 2 | Hypoglycemia, the most common adverse effect of IGF-1 (mecasermin label), expected to be more pronounced because LR3 escapes binding proteins |
| 3 | Class effects documented for IGF-1: tonsillar hypertrophy, intracranial hypertension, slipped capital femoral epiphysis in children, injection site lipohypertrophy |
| 4 | Theoretical promotion of tumor growth (IGF-1 signaling is mitogenic; mecasermin is contraindicated in cancer) |
| 5 | Anecdotal reports of jaw and hand growth and organ enlargement with prolonged use (not documented in studies) |
Interactions
| # | Interaction |
|---|---|
| 1 | No formal human interaction studies exist |
| 2 | Insulin and other glucose lowering drugs: additive hypoglycemia (IGF-1 class effect) |
| 3 | Growth hormone and growth hormone secretagogues: additive IGF-1 axis activity (not studied) |
| 4 | Corticosteroids blunt IGF-1 effects (animal data) |
Contraindications
| # | Contraindication |
|---|---|
| 1 | Active or suspected cancer (mecasermin label contraindication applied by class) |
| 2 | Closed epiphyses for growth promotion (mecasermin label) |
| 3 | Pregnancy and breastfeeding (no data) |
| 4 | Competitive athletes subject to WADA testing (prohibited at all times under S2) |
How do people access IGF-1 LR3 legally?
Typical cost: Not available through licensed channels. Products sold as research chemicals for human use are unapproved drugs and are not verified for identity or purity.
Access options
Not available
No lawful United States access path identified on the last verified date: it is not FDA approved and is not on the 503A bulks list.
Not available
Not available as an FDA approved product, not nominated for the 503A bulks list, and not eligible for compounding under section 503A or 503B.
Not available
Products labeled research use only are unapproved drugs when sold for human use and are not verified for identity or purity.
Access paths are checked against public regulatory records. Products labeled research use only are never listed.
Compare IGF-1 LR3
What's actually offered, and what that means for you
FDA has found a compounding pharmacy offering IGF-1 LR3 anyway. [7]
Being offered does not change the legal status of IGF-1 LR3. IGF-1 LR3 is not FDA approved and not on the 503A bulks list, so a pharmacy has no federal basis to compound it. [4] [8]
What FDA found
- April 2020: FDA named IGF-1 LR3 among the bulk substances a state-licensed 503A pharmacy compounded outside section 503A. [7]
Enforcement is uneven. FDA mostly acts through warning letters to compounders and online sellers, Category 2 safety listings, and import alerts that let it detain shipments, rather than stopping every pharmacy. State pharmacy boards oversee pharmacies day to day, and their rules differ. [8] [9] [10] [11] [12] [13]
What that means for you
- A pharmacy that compounds IGF-1 LR3 is taking a regulatory risk: it has no federal basis to do so, and FDA has sent warning letters to compounders for the same thing. [9] [10]
- No FDA oversight of the specific product: FDA does not check a compounded drug's safety, effectiveness, or quality before it is sold. [13]
- State boards can act. On August 19, 2026, Mississippi's medical, nursing, and pharmacy boards said no licensed provider may prescribe, recommend, supply, or administer a peptide that is not FDA approved, and that a consent form does not remove the provider's liability. [14]
- Louisiana acted by statute: Act 374, in effect August 1, 2026, bars its licensing boards from prohibiting peptides only when they come from a pharmacy or outsourcing facility that complies with federal compounding law. It does not make any peptide eligible to compound. [15] [16]
- Identity, purity, sterility, and dose accuracy can vary from batch to batch. [8]
- Insurance rarely covers it, so you usually pay cash.
- For tested athletes, IGF-1 LR3 is prohibited under the WADA Prohibited List, whatever the source. Some entries apply only in competition or only to male athletes, so check the section that covers it. [5]
If you're going ahead anyway
These steps lower some risks. They do not make the product safe, and they do not give a pharmacy a federal basis to compound IGF-1 LR3, with or without a prescription. [4]
Check the pharmacy's license. Look the pharmacy up yourself on your state board of pharmacy's license search; FDA's BeSafeRx page links every state's. If the pharmacy is not listed, or is not licensed in your state, do not use it. [17] [18] [19]
What a legitimate prescription and consult look like. Federal law lets a pharmacy compound only for an identified patient on a valid prescription. A legitimate prescriber is licensed in the state where you are, evaluates you, and tells you the drug is compounded and not FDA approved, and a telehealth company should say which pharmacy compounds it. A seller that needs no prescription, or a pharmacy with no pharmacist to answer questions, is a warning sign. [19] [20] [21]
Why this is safer than a research-use-only product. A state-licensed pharmacy answers to its state board and has a pharmacist you can reach. A product labeled "research use only" or "not for human consumption" has neither, and FDA treats such products sold for people as unapproved drugs. In a 2024 study of semaglutide sold online without a prescription, half of six orders never arrived, and every vial that did was rated probably substandard or falsified, held more drug than its label said, and contained endotoxin. Black-market growth peptides have also contained modified molecules the label did not name. Safer is not safe: compounded drugs can also be contaminated or have too much or too little active ingredient. [13] [22] [23] [24] [25] [26]
Check for:
- A 503A pharmacy licensed in your state (your state board of pharmacy publishes license lookups). [13]
- A real evaluation by a licensed prescriber, not just an online form.
- A certificate of analysis for the specific batch.
Questions to ask
- Pharmacy: What is your license number, and are you licensed in my state? Then check it yourself on the state board's site. [17]
- Telehealth company: Which pharmacy compounds and ships this, and is it a 503A pharmacy or a 503B outsourcing facility? [21]
- Pharmacy: Is this made for me on a prescription written in my name? [20]
- Prescriber: Are you licensed where I am, and will you evaluate me yourself rather than rely on a questionnaire? [19] [21]
- Prescriber: What is the legal basis for a pharmacy to compound IGF-1 LR3? Is it FDA approved or on the 503A bulks list? [4] [13]
- Anyone offering it: Does anyone call it "FDA approved", "generic", or from an "FDA-approved pharmacy"? None of these is true of a compounded drug, so the claim is a red flag. [21]
In Mississippi, there is no legitimate prescriber route for a peptide that is not FDA approved: licensed providers may not prescribe or supply one, and a patient who gets one on their own carries the risk alone. [14]
Frequently asked questions
What is IGF-1 LR3?
IGF-1 LR3 (long arginine 3 IGF-1) is a lab-made version of insulin-like growth factor 1, a growth factor the body makes in response to growth hormone, with a 13 amino acid extension at one end and an arginine swapped in at position 3. Those changes reduce binding to IGF binding proteins (blood proteins that normally hold IGF-1 in check), and it was 2 to 3 times more anabolic (tissue building) than native IGF-1 in rats. It was built as a research reagent, a lab tool; no human study has been published, and it is not the approved IGF-1 drug mecasermin. [1] [2] [3]
Is IGF-1 LR3 legal?
It is not an FDA approved drug and has never been reviewed by FDA. It cannot be compounded because it is not a component of an approved drug and is not on the 503A bulks list. The only products on the market are research reagents, which are unapproved drugs when sold for human use. Possession is not a crime, but no licensed channel can lawfully supply it for injection. The approved human IGF-1, mecasermin, is a different molecule restricted to children with severe IGF-1 deficiency. [3] [4] [6]
Does IGF-1 LR3 build muscle?
In rats, it is strongly anabolic: about 2.5 times more potent than native IGF-1 at restoring body weight and nitrogen balance in a catabolic model, with reduced muscle protein breakdown. In humans nobody knows, because no study has ever given LR3 IGF-1 to people. The rat data also showed that it enlarged the gut by up to 45%, which hints at effects beyond skeletal muscle. PeptideAgent grades the evidence animal-only. [1] [2]
What are the side effects of IGF-1 LR3?
There are no human safety data for LR3 itself. The approved native IGF-1 (mecasermin) label lists hypoglycemia as the most common adverse effect, plus tonsillar enlargement, intracranial hypertension, and injection site fat growth, and it is contraindicated in cancer because IGF-1 signaling drives cell growth. LR3 is designed to have more free activity than IGF-1, so hypoglycemia is expected to be worse. Reports of jaw growth and organ enlargement with prolonged use are anecdotal. [2] [3]
How much does IGF-1 LR3 cost?
There is no licensed source and therefore no legitimate price. Products sold as research chemicals for human use are unapproved drugs and are not verified for identity or purity. [4] [6]
Is IGF-1 LR3 banned by WADA?
Yes. The WADA Prohibited List names insulin-like growth factor 1 (IGF-1) and its analogues under section S2 (peptide hormones, growth factors, related substances and mimetics), prohibited at all times. LR3 IGF-1 is an IGF-1 analog by definition. [5]
IGF-1 LR3 vs mecasermin (Increlex): what is the difference?
Mecasermin is native recombinant human IGF-1, FDA approved in 2005 for children with severe primary IGF-1 deficiency, dosed under specialist care with a known safety profile. IGF-1 LR3 is an engineered analog with an N-terminal extension and an arginine substitution that stop it binding IGF binding proteins, made for cell culture and never tested in humans. They are not interchangeable, and mecasermin's approval gives LR3 no federal basis to be compounded. [1] [3]
Decisions about starting, stopping, or combining any treatment belong with a licensed clinician who knows your history.
From the blog
- Peptides for muscle growth, ranked by human evidence
MK-677, sermorelin, tesamorelin, CJC-1295, IGF-1 LR3, and more ranked by human evidence. None is approved for muscle growth, and all ten are banned in tested sport.
- Peptides for tendon recovery, ranked by human evidence
BPC-157, TB-500, GHK-Cu, PEG-MGF, and IGF-1 LR3 ranked by our evidence grades. None has a published human tendon trial. Here is the ranking, the reasoning, and what does have human data.
- What are peptides? A plain-English guide
Peptides are short chains of amino acids. Some are FDA approved medicines, some are compounded, and many are unapproved research chemicals. Here is how to tell them apart.
Sources
Numbered citations above point to these primary sources. PubMed entries link to the indexed abstract.
- [1]Francis GL et al. Novel recombinant fusion protein analogues of insulin-like growth factor (IGF)-I indicate the relative importance of IGF-binding protein and receptor binding for enhanced biological potency. J Mol Endocrinol 1992PubMed 1378742, 1992
- [2]Tomas FM et al. Insulin-like growth factor-I (IGF-I) and especially IGF-I variants are anabolic in dexamethasone-treated rats. Biochem J 1992PubMed 1371669, 1992
- [3]FDA prescribing information for Increlex (mecasermin) injection, via DailyMedFDA, 2024
- [4]FDA: Bulk drug substances used in compounding under section 503A of the FD&C Act (links to the Category 1, 2, and 3 lists and the bulks list)FDA, 2026
- [5]WADA Prohibited List, section S2 (names IGF-1 and its analogues)WADA, 2026
- [6]FDA warning letter 735063, August 24, 2026, to an online seller of research-use-only peptides: products labeled research use only were unapproved new drugs (FDA warning letters database)FDA, 2026
- [7]FDA warning letter 594743, April 1, 2020, to a state-licensed 503A compounding pharmacy (FDA warning letters database)FDA, 2020
- [8]FDA: Certain bulk drug substances for use in compounding may present significant safety risks (Category 2)FDA
- [9]FDA: Compounding inspections, recalls, and other actions (warning letters to compounders)FDA
- [10]FDA warning letter 579286, July 30, 2019, to a state-licensed 503A compounding pharmacy (FDA warning letters database)FDA, 2019
Cite this page
Free to cite and quote with a link. Data is licensed CC BY 4.0 with attribution to PeptideAgent.
- APA style
PeptideAgent. (2026, September 23). IGF-1 LR3: evidence, legality, and access. https://peptideagent.ai/peptides/igf-1-lr3- HTML link
<a href="https://peptideagent.ai/peptides/igf-1-lr3">IGF-1 LR3: evidence, legality, and access</a>, PeptideAgent, updated September 23, 2026.